BioWorld

March 5, 2003

View Archived Issues

ILEX Gets Non-Oncology Rights To Campath Leukemia Treatment

In Vivo Adenoviral Gene Transfer Inefficient In Aged Cardiac Muscle In Comparison With Adult Hearts

YM BioSciences Receives FDA Nod For Phase III Cancer Trial

Viragen Continues Restructuring To Sustain Remaining Resources

Aphton Releases Phase III Data, Prepares For Regulatory Filings

Other News To Note

TNF Drugs Not Implicated In Lymphoma Risk, Panel Says

The risk of lymphoma in the rheumatoid arthritis population doesn't appear to increase among patients taking a TNF blocker, members of an FDA advisory panel said on Tuesday. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...